Clinical Trial Update: FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

FK-PC101 is being evaluated as adjuvant therapy for high-risk prostate cancer in a Phase 2 trial that is currently recruiting. The study is sponsored by Cellvax…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• FK-PC101

Snippet

Sponsor: Cellvax Therapeutics Inc | Conditions: Prostate Cancer (Adenocarcinoma), Prostate CA | Phase 2 | Status: RECRUITING